BGI Genomics(SZ:300676) Jing Ji Guan Cha Wang·2025-10-24 00:42Core Viewpoint - 华大基因 reported a significant increase in profitability despite industry challenges, with a notable rise in net profit and effective cost management [1][2][3] Financial Performance - The company achieved a revenue of 2.674 billion yuan in the first three quarters, with a year-on-year net profit increase of 82.78% and a non-recurring net profit increase of 52.04% [1] - In Q3 alone, revenue reached 1.042 billion yuan, marking a 9.19% year-on-year growth, while net profit surged by 80.92% [1] Business Segment Analysis - Fertility Health Business: Revenue declined to 643 million yuan, primarily due to a 36% drop in non-invasive prenatal testing revenue, influenced by structural changes in revenue accounting [1][2] - Tumor and Chronic Disease Prevention: Revenue slightly decreased to 358 million yuan, attributed to reduced client demand for testing services, with a notable 9% growth in colorectal cancer detection revenue [2] - Infection Control Business: Revenue increased by 41.7% to 75 million yuan, driven by advancements in pathogen sequencing and automation, with PTseq product revenue growing by approximately 200% [2] - Multi-Omics and Synthetic Business: Revenue remained stable at 452 million yuan, with single-cell sequencing showing a significant growth of about 93% [3] - Precision Medicine Testing Solutions: Revenue grew by 11.2% to 1.124 billion yuan, bolstered by successful overseas project implementations [3] Strategic Adjustments - The company is focusing on high-margin products and expanding into emerging overseas markets, particularly in Latin America, to counteract pricing pressures in core products [2] - Continuous operational efficiency improvements through refined management practices are expected to support sustainable growth [3]